Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen to Use NIH Grants with NCI, USC in Lentiviral Vector Therapy Studies

NEW YORK (GenomeWeb News) – Lentigen said yesterday it will use four grants from the National Institutes of Health to develop novel treatments for several diseases.
 
Lentigen, a lentiviral vector technology developer, said it will use the four small business innovation research grants to fund studies in melanoma and hepatitis C virus in collaboration with Michael Nishimura of the University of South Carolina, and studies of Epstein-Barr virus-related diseases and chronic lymphocytic leukemia in collaboration with Adrian Wiestner at the National Cancer Institute.
 
Baltimore-based Lentigen will work with these collaborators to develop lentiviral vectors, which are used to deliver genes or gene silencing sequences into cells and target specific diseases.
 
The company did not release the dollar value of the SBIR grants.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.